Mikkel Malham1, Christian Jakobsen1,2, Anders Paerregaard1, Lauri J Virta3, Kaija-Leena Kolho4,5, Vibeke Wewer1. 1. The Paediatric Department, Copenhagen University Hospital, Hvidovre, Denmark. 2. The Gastro Unit, Medical Division, Copenhagen University Hospital, Hvidovre, Denmark. 3. The Research Department, The Social Insurance Institution, Turku, Finland. 4. The Paediatric Department, Tampere University Hospital and Tampere University, Tampere, Finland. 5. Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Abstract
BACKGROUND: Recent studies report increased risks of both cancer and mortality in paediatric onset inflammatory bowel disease (pIBD) but the reproducibility of this is unknown. AIM: To estimate the risk of cancer and mortality in the Danish and Finnish pIBD population in a 23-year period compared to the general population. METHODS: The pIBD population was defined as individuals registered in the national patient registries with a diagnosis of Crohn's disease (CD), ulcerative colitis (UC) or IBD-unclassified before their 18th birthday from 1992 to 2014. This cohort was cross referenced with the national cancer and mortality registries identifying all pIBD patients who subsequently developed cancer and/ or died and followed up to the end of 2014. Risk estimates are presented as standardised incidence ratios calculated based on incidence figures from the populations. RESULTS: Six thousand six hundred and eight-nine patients with pIBD were identified (median age at follow-up 22.3 years; median follow-up: 9.6 years [interquartile range: 4.8-16.0]). Seventy-two subsequently developed cancer and 65 died. The standardised incidence ratio of cancer in general was 2.6 (95% CI: 1.8-3.7) and 2.5 (95% CI: 1.8-3.4) in CD and UC, respectively. The standardised mortality ratios were 2.2 (95% CI: 1.4-3.4) and 3.7 (95% CI: 2.7-5.0) in CD and UC, respectively. The leading causes for mortality were cancer, suicide and infections. CONCLUSIONS: We found an increased risk of cancer and mortality in pIBD. This underlines the importance of cancer surveillance programs and assessment of mental health in the standard of care in adolescent pIBD patients.
BACKGROUND: Recent studies report increased risks of both cancer and mortality in paediatric onset inflammatory bowel disease (pIBD) but the reproducibility of this is unknown. AIM: To estimate the risk of cancer and mortality in the Danish and Finnish pIBD population in a 23-year period compared to the general population. METHODS: The pIBD population was defined as individuals registered in the national patient registries with a diagnosis of Crohn's disease (CD), ulcerative colitis (UC) or IBD-unclassified before their 18th birthday from 1992 to 2014. This cohort was cross referenced with the national cancer and mortality registries identifying all pIBD patients who subsequently developed cancer and/ or died and followed up to the end of 2014. Risk estimates are presented as standardised incidence ratios calculated based on incidence figures from the populations. RESULTS: Six thousand six hundred and eight-nine patients with pIBD were identified (median age at follow-up 22.3 years; median follow-up: 9.6 years [interquartile range: 4.8-16.0]). Seventy-two subsequently developed cancer and 65 died. The standardised incidence ratio of cancer in general was 2.6 (95% CI: 1.8-3.7) and 2.5 (95% CI: 1.8-3.4) in CD and UC, respectively. The standardised mortality ratios were 2.2 (95% CI: 1.4-3.4) and 3.7 (95% CI: 2.7-5.0) in CD and UC, respectively. The leading causes for mortality were cancer, suicide and infections. CONCLUSIONS: We found an increased risk of cancer and mortality in pIBD. This underlines the importance of cancer surveillance programs and assessment of mental health in the standard of care in adolescent pIBD patients.
Authors: Mohamed Attauabi; Gorm Roager Madsen; Flemming Bendtsen; Anne Vibeke Wewer; Rune Wilkens; Johan Ilvemark; Nora Vladimirova; Annette Bøjer Jensen; Frank Krieger Jensen; Sanja Bay Hansen; Hartwig Roman Siebner; Yousef Jesper Wirenfeldt Nielsen; Jakob M Møller; Henrik S Thomsen; Simon Francis Thomsen; Helene Andrea Sinclair Ingels; Klaus Theede; Trine Boysen; Jacob T Bjerrum; Christian Jakobsen; Maria Dorn-Rasmussen; Sabine Jansson; Yiqiu Yao; Ewa Anna Burian; Frederik Trier Møller; Viktoria Fana; Charlotte Wiell; Lene Terslev; Mikkel Østergaard; Kristina Bertl; Andreas Stavropoulos; Jakob B Seidelin; Johan Burisch Journal: BMJ Open Date: 2022-06-27 Impact factor: 3.006
Authors: Min Jee Kim; Jae Sung Ko; Minsoo Shin; Jong Woo Hahn; Soo Young Moon; Hyun Young Kim; Jin Soo Moon Journal: BMC Pediatr Date: 2021-11-11 Impact factor: 2.125